Barclays
ASBP

Barclays’s Aspire Biopharma ASBP Stock Holding History

Barclays’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-583
Closed -$7.35M – 5169
2023
Q1 		$7.35M Hold
583
– – ﹤0.01% 1317
2022
Q4 		$7.21M Hold
583
– – ﹤0.01% 1386
2022
Q3 		$7.1M Hold
583
– – 0.01% 987
2022
Q2 		$6.99M Buy
+583
New +$6.98M ﹤0.01% 1173

Other funds holding ASBP

PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
AI
Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
ETH
Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

Barclays's ASBP Position: Q2 2023 in Review

Barclays sold out of Aspire Biopharma (ASBP) in Q2 2023, closing a stake of 583 shares — an estimated $7.35M sold.

Barclays first reported a position in ASBP in Q2 2022 and held it in 4 quarters. The position peaked at $7.35M in Q1 2023. 14 funds tracked by Wall St. Rank hold ASBP as of Q2 2023.

  • Barclays reported no remaining Aspire Biopharma position as of Q2 2023 after selling out during the quarter.
  • Barclays sold 583 Aspire Biopharma shares in Q2 2023, an estimated $7.35M.
  • Barclays first reported a position in Aspire Biopharma in Q2 2022 and held it in 4 quarters.
  • Barclays's Aspire Biopharma position peaked at $7.35M in Q1 2023.
  • 14 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2023.

Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.